Tisztelt Kutatók!

Megjelentek a SCImago Journal & Country Rank 2024-re vonatkozó folyóirat értékelései.

https://www.scimagojr.com/

Hot Papers

A Web of Science adatbázis által definiált tudománymetriai mutató. Azok a közlemények kerülnek ebbe a kategóriába, amelyek az elmúlt 2 évben jelentek meg és 2024. november és december hónapban kiemelkedő számú hivatkozást kaptak saját tudományterületükön, az adatokat kéthavonta frissítik.

Gaudet, D., Páll, D., Watts, G. F., Nicholls, S. J., Rosenson, R. S., Modesto, K., San Martin, J., Hellawell, J., Ballantyne, C. M.: Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: the SHASTA-2 Randomized Clinical Trial.
JAMA Cardiol. [Epub ahead of print], 2024.

doi DEA WoS Scopus

Folyóirat-mutatók:

D1 Cardiology and Cardiovascular Medicine

Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., Acevedo, A., Sukhin, V., Cloven, N., Santana Gomes, A. J. P. d., Contreras Mejía, F., Reiss, A., Ayhan, A., Lee, J. Y., Saevets, V., Zagouri, F., Gilbert, L., Sehouli, J., Tharavichitkul, E., Lindemann, K., Lazzari, R., Chang, C. L., Lampé, R., Zhu, H., Oaknin, A., Christiaens, M., Polterauer, S., Usami, T., Li, K., Yamada, K., Toker, S., Keefe, S. M., Pignata, S., Duska, L. R., ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet. 403 (10434), 1341-1350, 2024.

doi DEA WoS Scopus

Folyóirat-mutatók:

D1 Medicine (miscellaneous)

Pratz, K. W., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Döhner, H., Recher, C., Fiedler, W., Yamamoto, K., Wang, J., Yoon, S. S., Wolach, O., Yeh, S. P., Leber, B., Esteve, J., Mayer, J., Porkka, K., Illés, Á., Lemoli, R. M., Turgut, M., Ku, G., Miller, C., Zhou, Y., Zhang, M., Chyla, B., Potluri, J., DiNardo, C. D.: Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am. J. Hematol. 99 (4), 615-624, 2024.

doi DEA WoS Scopus

Folyóirat-mutatók:

D1 Hematology

Hayrapetyan, A., CMS Collaboration, ATLAS Collaboration: Combination of Measurements of the Top Quark Mass from Data Collected by the ATLAS and CMS Experiments at root{s} = 7 and 8 TeV.
Phys. Rev. Lett. 132 (26), 1-37, (cikkazonosító: 261902), 2024.

doi DEA WoS Scopus

GBD 2021 Diseases and Injuries Collaborators: Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Lancet. 403 (10440), 2133-2161, 2024.

doi DEA WoS Scopus

GBD 2021 Fertility and Forecasting Collaborators: Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
Lancet. 403 (10440), 2057-2099, 2024.

doi DEA WoS Scopus

GBD 2021 Demographics Collaborators: Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
Lancet. 403 (10440), 1989-2056, 2024.

doi DEA WoS Scopus

GBD 2021 Causes of Death Collaborators: Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Lancet. 403 (10440), 2100-2132, 2024.

doi DEA WoS Scopus